Logo image of OSTX

OS THERAPIES INC (OSTX) Stock Fundamental Analysis

NYSEARCA:OSTX - NYSE Arca - US68764Y2072 - Common Stock - Currency: USD

2.03  +0.03 (+1.5%)

After market: 2.07 +0.04 (+1.97%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OSTX. OSTX was compared to 566 industry peers in the Biotechnology industry. While OSTX seems to be doing ok healthwise, there are quite some concerns on its profitability. OSTX has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OSTX had negative earnings in the past year.
In the past year OSTX has reported a negative cash flow from operations.
OSTX Yearly Net Income VS EBIT VS OCF VS FCFOSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -196.54%, OSTX is doing worse than 89.40% of the companies in the same industry.
With a Return On Equity value of -1341.48%, OSTX is not doing good in the industry: 84.10% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -196.54%
ROE -1341.48%
ROIC N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSTX Yearly ROA, ROE, ROICOSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OSTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSTX Yearly Profit, Operating, Gross MarginsOSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for OSTX has been increased compared to 1 year ago.
There is no outstanding debt for OSTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OSTX Yearly Shares OutstandingOSTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
OSTX Yearly Total Debt VS Total AssetsOSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M

2.2 Solvency

Based on the Altman-Z score of -8.50, we must say that OSTX is in the distress zone and has some risk of bankruptcy.
OSTX has a Altman-Z score of -8.50. This is in the lower half of the industry: OSTX underperforms 70.67% of its industry peers.
OSTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.5
ROIC/WACCN/A
WACCN/A
OSTX Yearly LT Debt VS Equity VS FCFOSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

OSTX has a Current Ratio of 1.20. This is a normal value and indicates that OSTX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.20, OSTX is not doing good in the industry: 85.69% of the companies in the same industry are doing better.
OSTX has a Quick Ratio of 1.20. This is a normal value and indicates that OSTX is financially healthy and should not expect problems in meeting its short term obligations.
OSTX has a Quick ratio of 1.20. This is amonst the worse of the industry: OSTX underperforms 84.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.2
OSTX Yearly Current Assets VS Current LiabilitesOSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

OSTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -128.56%.
EPS 1Y (TTM)-128.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-451.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OSTX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.40% on average per year.
The Revenue is expected to grow by 464.63% on average over the next years. This is a very strong growth
EPS Next Y163.44%
EPS Next 2Y40.09%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue Next Year26664%
Revenue Next 2Y1030.05%
Revenue Next 3Y464.63%
Revenue Next 5YN/A

3.3 Evolution

OSTX Yearly Revenue VS EstimatesOSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 10M 20M 30M
OSTX Yearly EPS VS EstimatesOSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSTX. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 2.94, the valuation of OSTX can be described as very cheap.
Based on the Price/Forward Earnings ratio, OSTX is valued cheaper than 99.12% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.20, OSTX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 2.94
OSTX Price Earnings VS Forward Price EarningsOSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSTX Per share dataOSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as OSTX's earnings are expected to grow with 24.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.09%
EPS Next 3Y24.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OSTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OS THERAPIES INC

NYSEARCA:OSTX (4/30/2025, 8:27:58 PM)

After market: 2.07 +0.04 (+1.97%)

2.03

+0.03 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)N/A N/A
Inst Owners0.77%
Inst Owner Change0%
Ins Owners20.37%
Ins Owner Change7.85%
Market Cap43.97M
Analysts82.22
Price Target16.07 (691.63%)
Short Float %2.98%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.61%
Min EPS beat(2)-64.16%
Max EPS beat(2)-47.06%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.39%
PT rev (3m)24.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.25%
EPS NY rev (3m)-53.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.94
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 54.18
P/tB 54.18
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)0.69
Fwd EY34%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -196.54%
ROE -1341.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-813.87%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.2
Quick Ratio 1.2
Altman-Z -8.5
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-128.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-451.58%
EPS Next Y163.44%
EPS Next 2Y40.09%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year26664%
Revenue Next 2Y1030.05%
Revenue Next 3Y464.63%
Revenue Next 5YN/A
EBIT growth 1Y-56.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-142.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.18%
OCF growth 3YN/A
OCF growth 5YN/A